. 2021 Jan 18;10(8):918–926. doi: 10.1002/cpdd.903
© 2021 Kartos Therapeutics, Inc. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Figure 1.
Structure of KRT‐232 and acyl glucuronide metabolite M1.